Zynex Inc stock (US98986M1036): Medical device innovator with steady growth

Zynex Inc, a leader in non-invasive pain management devices, continues to expand its product portfolio and US market presence, offering retail investors exposure to the growing electrotherapy sector.

Zynex Inc develops and markets non-invasive medical devices primarily for pain management and rehabilitation. The company, listed on Nasdaq under ZYXI, focuses on electrotherapy products like the NexWave and Tens units, which are used in hospitals, clinics, and home settings across the US. Recent financial reports highlight consistent revenue growth driven by increasing adoption in the healthcare sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zynex Inc
• Sector/industry: Medical Devices / Electrotherapy
• Headquarters/country: United States
• Core markets: US healthcare providers
• Key revenue drivers: Pain management devices, rehabilitation systems
• Home exchange/listing venue: Nasdaq (ZYXI)
• Trading currency: USD

Zynex Inc: core business model

Zynex Inc specializes in innovative, non-invasive medical technologies designed to treat chronic and acute pain without the need for pharmaceuticals or surgery. The company's flagship products include the NexWave TENS device, which delivers targeted electrical stimulation to alleviate pain, and the E-Wave system for muscle rehabilitation. These devices are FDA-cleared and widely used by physical therapists, orthopedists, and pain specialists. Zynex operates a direct sales model in the US, supplemented by distribution partnerships, allowing it to reach over 90% of the domestic market efficiently. This approach minimizes costs while maximizing penetration in the $10 billion US pain management device sector.

Founded in 1996 and headquartered in Englewood, Colorado, Zynex has built a portfolio of more than 20 patented products. Its business model emphasizes recurring revenue from disposable electrodes and accessories, which account for approximately 40% of sales. The company invests heavily in R&D, allocating about 8-10% of revenue annually to develop next-generation devices with wireless capabilities and AI-driven therapy adjustments. For US investors, Zynex provides exposure to the aging population trend, where demand for non-opioid pain solutions is surging amid the opioid crisis.

Main revenue and product drivers for Zynex Inc

Zynex generates the majority of its revenue from its Pain Management Division, which contributed over 70% in recent quarters. Key products like the NexWave and INFERNO Wrap systems drive sales through hospital contracts and direct-to-consumer channels via telemedicine integrations. The Rehabilitation Products Division, including the NeuroMove stroke recovery device, adds diversified income, particularly from long-term care facilities. International expansion into Europe and Asia, though nascent at under 10% of revenue, is accelerating via CE-marked approvals.

Sales growth has been fueled by strategic acquisitions and organic innovation. For instance, the 2023 launch of the Zynex Fluid Management System expanded into surgical applications, tapping a new $2 billion addressable market. Disposable supplies remain a high-margin driver, with gross margins exceeding 60%. US investors benefit from Zynex's strong positioning in Medicare-reimbursed therapies, insulating it from private payer volatility.

Industry trends and competitive position

The electrotherapy market is projected to grow at 7% CAGR through 2030, driven by rising chronic pain prevalence affecting 50 million US adults. Zynex competes with larger players like Medtronic and DJO Global but differentiates through affordability and clinician-focused design. Its devices offer superior battery life and patient compliance rates, leading to higher repeat orders. Recent sector shifts toward home-based care post-COVID have boosted Zynex's portable units, aligning with telehealth expansion.

Zynex holds a niche leadership in electrical stimulation for post-surgical pain, with clinical studies validating efficacy comparable to opioids but without addiction risks. Barriers to entry include FDA hurdles and patent protections on waveform technology, giving Zynex a defensible moat.

Why Zynex Inc matters for US investors

As a Nasdaq-listed small-cap, Zynex offers US retail investors direct access to medtech innovation without the premiums of mega-caps. Its products address the US healthcare system's push for non-pharmacological alternatives, supported by CMS reimbursement codes. Exposure to domestic manufacturing reduces supply chain risks, unlike peers reliant on Asia. With the US accounting for 85% of revenue, Zynex mirrors American economic health in wellness spending.

Conclusion

Zynex Inc stands out in the medtech space with its focus on non-invasive pain solutions amid favorable industry tailwinds. Steady revenue from core products and expansion into adjacent areas position it for continued relevance. US investors track its progress through quarterly updates and market adoption metrics. The company's evolution reflects broader shifts in healthcare delivery.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.